Ruzanna Papyan, Chief of Pediatric Oncology Department at PCBDC of Armenia, Clinical Research Physician at Immune Oncology Research Institute, shared a post on LinkedIn:
“Join us for the next Global Neuroblastoma Network (GNN) Educational Session
Thursday, 7 May 2026
8:30 AM EST
We are pleased to welcome Paola Angelini and Benjamin Lerman who will lead a discussion on:
Should we use bevacizumab or dinutuximab with irinotecan and temozolomide for resistant neuroblastoma?
This session will focus on real-world decision-making in a challenging clinical setting—highly relevant for clinicians managing relapsed/refractory disease
Other articles featuring Ruzanna Papyan on OncoDaily.